<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02396628</url>
  </required_header>
  <id_info>
    <org_study_id>RIG-P000814</org_study_id>
    <secondary_id>2014-004267-20</secondary_id>
    <secondary_id>DRKS00007939</secondary_id>
    <nct_id>NCT02396628</nct_id>
  </id_info>
  <brief_title>Ruxolitinib In GvHD</brief_title>
  <acronym>RIG</acronym>
  <official_title>Multicentre Phase 2 Trial to Evaluate the Efficacy of Ruxolitinib in Steroid-refractory Acute Multicenter, Randomized Phase 2 Trial to Determine the Response Rate of Ruxolitinib and Best Available Treatment (BAT) Versus BAT in Steroid-refractory Acute Graft-versus-Host Disease (aGvHD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Dr. Nikolas von Bubnoff</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clinical Trials Unit Freiburg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Freiburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The preliminary data demonstrate potent activity of Ruxolitinib in steroid-refractory aGvHD.
      In this phase 2 trial the efficacy of Ruxolitinib and best available treatment (BAT) versus
      BAT in steroid-refractory acute GvHD in approximately 12 transplantation centers in Germany
      will be compared. The response by monitoring the clinical GvHD grade, requirement of
      alternative GvHD active agents and serum levels of pro-inflammatory cytokines will be
      determined.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pathophysiological hallmark of GvHD after allo-HCT is an allogeneic donor T cell
      re-sponse against recipient antigens. This process is aggravated by increased processing and
      presentation of host antigens by donor APCs following conditioning treatment. The al-logeneic
      T cell response leads to inflammation, tissue damage and fibrosis and is mediated by
      extensive production of inflammatory cytokines such as IL-1, IL-2R, IL-6 and TNF. The signal
      transmission of inflammatory cytokines in effector cells requires activation of specialized
      kinases from the family of the Janus kinases. These kinases, JAK1, 2 and 3 are linked to
      cytokine receptors, and are activated upon binding of the cytokine to the receptor of the
      inflammatory effector. The JAK1/2 kinase inhibitor Ruxolitinib (INC424) is approved for
      myelofibrosis. In advanced myelofibrosis, Ruxolitinib lead to sustained clinical remissions
      with regard to constitutional symptoms, weight loss and spleen size in the majority of
      treated patients. Of note, clinical responses correlated with a marked reduction in
      inflammatory plasma cytokines.

      Importantly, cytokines down-regulated by Ruxolitinib in patients with myelofibrosis
      correspond to inflammatory effectors that mediate tissue damage and inflammation in GvHD.
      These are mainly the cytokines IL- 1, IL -6, TNF and IFN-gamma. Since Ruxolitinib suppresses
      the JAK1 / 2 cytokine response, we hypothesized that Ruxolitinib might attenuate the cytokine
      mediated inflammatory tissue damage in GVHD and thus might favourably affect the severity and
      course of GvHD after allo-HCT.

      In vitro, we demonstrated in an allogeneic system (major mismatch mixed-lymphocyte reactions)
      that co-incubation with Ruxolitinib strongly suppressed both the proliferation of alloge-neic
      T cells and the production of inflammatory cytokines. Using a very aggressive major mismatch
      mouse model of acute GvHD Ruxolitinib treatment signifi-cantly prolonged survival of animals
      (see Figure 1A). In addition, in these animals showed a reduced weight loss, significantly
      reduced histopathological GvHD severity, suppression of inflammatory cytokines in the serum
      and a reduction of donor T cells in GvHD target organs such as the intestines.

      Sole suppression of cytokine production or cytokine receptor activity by Ruxolitinib would be
      very similar to already established drugs for GvHD and no major conceptual advance. However
      we observed that Ruxolitinib did not only suppress cytokine production but also led to
      increased frequencies of FoxP3+ regulatory T cells. This cell type was previ-ously shown to
      lead to long-lasting tolerance as compared to the short-term immunosuppression achieved by
      conventional medication for GvHD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 29, 2017</start_date>
  <completion_date type="Anticipated">January 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>efficacy of Ruxolitinib and BAT as compared to BAT alone at day 28 after treatment start</measure>
    <time_frame>at day 28 after treatment start</time_frame>
    <description>To evaluate efficacy of Ruxolitinib and BAT as compared to BAT alone at day 28 after treatment start in steroid-refractory acute GvHD, measured as response rate</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Graft vs Host Disease</condition>
  <arm_group>
    <arm_group_label>Experimental intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of August 2015). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Experimental intervention</intervention_name>
    <description>Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines</description>
    <arm_group_label>Experimental intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Standard treatment</intervention_name>
    <description>Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of August 2015). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.</description>
    <arm_group_label>Standard treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute skin, intestinal or liver GvHD &gt; grade 1 according to standard criteria

          2. Histological confirmation in case of acute intestinal GvHD

          3. Age â‰¥18 years

          4. Failure of previous treatment, defined as presence of at least one of the following
             criteria:

               1. Treatment with prednisone/prednisolone/methylprednisolone in a dose of at least 2
                  mg/kg and lack of response after at least 7 days treatment

               2. Treatment with prednisone/prednisolone/methylprednisolone in a dose of at least 2
                  mg/kg and progression after at least 3 days of treatment

               3. Failure to taper the prednisone/prednisolone dose to 0.6 mg/kg/day or
                  methylpredniso-lone dose to &lt;0.5 mg/kg/day

          5. Written informed consent

          6. Ability to understand the nature of the study and the study related procedures and to
             comply with them

        Exclusion Criteria:

          1. Uncontrolled underlying disease

          2. Active bleeding

          3. Absence of clinical signs of acute GvHD

          4. Diagnostic or distinctive clinical signs of chronic GvHD

          5. Uncontrolled bacterial, viral or fungal infection

          6. Any previous JAK2 inhibitor treatment prior to study enrolment, except Ruxolitinib
             given prior to the allogeneic stem cell transplantati

          7. Known Hypersensitivity to Ruxolitinib or any of the excipients

          8. Known positivity for HIV, Hepatitis B or Hepatitis C at the time of screening.

          9. Female patients who are pregnant or breast feeding

         10. Concomitant use of any other investigational drug within the last thirty days before
             the start of this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nikolas von Bubnoff, Professor</last_name>
    <phone>+49 761 270-</phone>
    <phone_ext>33210</phone_ext>
    <email>nikolas.bubnoff@uniklinik-freiburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Zeiser, Professor</last_name>
    <phone>+49 761 270-</phone>
    <phone_ext>36250</phone_ext>
    <email>robert.zeiser@uniklinik-freiburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CharitÃ© - UniversitÃ¤tsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Igor Blau, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Il-Kang Na, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Giang Lam Vuong, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Bonn</name>
      <address>
        <city>Bonn</city>
        <zip>53105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dominik Wolf, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karin Mayer, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Friedrich StÃ¶lzel, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rainer Ordemann, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Medical Center</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolas von Bubnoff, Professor</last_name>
      <email>nikolas.bubnoff@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Nikolas von Bubnoff, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Zeiser, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Hamburg Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francis Ayuk, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dietlinde Janson, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Peter Dreger, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thomas Luft, PD Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>JÃ¶rg T. Bittenbring, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>JÃ¶rg T. Bittenbring, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Pfreundschuh, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inken Hilgendorf, PD Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Inken Hilgendorf, PD Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nils Winkelmann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum KÃ¶ln</name>
      <address>
        <city>KÃ¶ln</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Udo Holtick, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Udo Holtick, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christof Scheid, Prof.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35043</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Andreas Burchert, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Burchert, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristina Sohlbach, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum MÃ¼nchen TU rechts der Isar</name>
      <address>
        <city>MÃ¼nchen</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mareike Verbeek, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Grass, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitÃ¤tsklinikum WÃ¼rzburg</name>
      <address>
        <city>WÃ¼rzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>GÃ¶tz Grigoleit, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthias Hermann, Dr.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 10, 2015</study_first_submitted>
  <study_first_submitted_qc>March 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 24, 2015</study_first_posted>
  <last_update_submitted>September 26, 2017</last_update_submitted>
  <last_update_submitted_qc>September 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Freiburg</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Nikolas von Bubnoff</investigator_full_name>
    <investigator_title>Coordinating Investigator</investigator_title>
  </responsible_party>
  <keyword>Graft-versus-Host Disease (GvHD)</keyword>
  <keyword>resistance to therapy</keyword>
  <keyword>allogeneic stem cell transplantation</keyword>
  <keyword>Ruxolitinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

